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Abstract 
Zeta potential is a scientific term for electrokinetic potential in colloidal systems which has a major effect 
on the various properties of nano-drug delivery systems. Presently, colloidal nano-carriers are growing 
at a remarkable rate owing to their strong potential for overcoming old challenges such as poor drug 
solubility and bioavailability. Furthermore, they show an unlimited capacity in the field of drug targeting. 
The properties of nano-medicines such as release from dosage forms at specific sites as well as drug 
circulation and absorption into body membranes are dramatically affected by some physical and 
chemical characteristics of nano-drugs. Particle size and charge are two major factors which could play 
key roles in this regard. In this paper, the effect of zeta potential on different properties of nano-drug 
delivery systems is reviewed.  
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Zeta potential (ZP) 
 
Zeta potential is a scientific term for electrokinetic 
potential in colloidal systems, i.e., electric 
potential in the interfacial double layer at the 
location of the slipping plane versus a point in the 
bulk fluid away from the interface [1]. This term 
expresses the potential difference between the 
dispersion medium and the stationary layer of 
fluid attached to the dispersed particle. Although 
zeta potential is not equal to the Stern potential 
or electric surface potential in the double layer, it 
is often the only available path for the 
characterization of double-layer properties [1].  
 
Coulomb interactions are the strongest physical 
forces between any two objects. Electrokinetic or 
ζ-potential is defined as the average electrostatic 
potential existing at the hydrodynamic plane of 
shear, somewhere between the Stern plane and 
the end of the diffuse layer, normally considered 
to be 0.2 nm from the surface [2,3]. On the other 
hand, the electric double layer formed at the 
boundary between a solid surface and an 
electrolyte solution determines its electrokinetic 
(interfacial double layer or charge) properties. 
Thus, zeta potential can be defined as the 
electrokinetic value associating a realistic 
magnitude of surface charge [4-9]. Measurement 
of ζ-potential is currently the simplest and most 
straightforward way to characterize the surface of 
charged colloids, and conclusions are easily 
drawn from the analysis of its data regarding 
concentration, distribution, adsorption, ionisation, 
exposure or shielding of charged moieties [3]; its 
unit is usually milivolt [7].  
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Zeta potential can affect the pharmacokinetic 
properties of nanosystems in the body [7,10] or 
may affect the phagocytosis of the nanoparticles 
in the blood stream [11-13]. Nanoparticles can be 
detected by electrostatic methods, by 
condensation on particles to grow them until they 
are measurable optically, or by other methods. 
Electrostatic methods require that the particles 
be charged and are not very sensitive [14].To 
fully characterize the charge conditions of 
particles, zeta potential measurements should be 
performed in distilled water and in the original 
dispersion medium of the suspension. Very 
often, ZP measurements are performed in 
buffers of varying molarities, physiological salt 
solution (some pharmacists think being 
physiological is a priori good) or other media. 
These measurements are rather meaningless for 
determining surface potential [15] or physical 
long-term stability under these measuring 
conditions [16]. 
 
Measurement of ZP 
 
Although ZP is not measurable directly, it can be 
calculated using theoretical models. 
Electrokinetic phenomena and electroacoustic 
phenomena are the usual sources of data for 
calculation of ZP. The ZP of a dispersion is 
measured by applying an electric field across the 
dispersion [17]. Particles within the dispersion 
with a ZP will migrate toward the electrode of 
opposite charge with a velocity proportional to 
the magnitude of the zeta potential. There are 
two different experimental techniques: 
microelectrophoresis which has the advantage of 
yielding an image of the moving particles, and 
electrophoretic light scattering which is based on 
dynamic light scattering. The latter can be used 
to characterize very small particles. The 
frequency shift or phase shift of an incident laser 
beam caused by these moving particles is 
measured as the particle mobility, and this 
mobility is converted to ZP using Smoluchowski 
or Huckel theory. Both of these methods may 
require dilution of the sample. Sometimes, this 
dilution might affect the properties of the sample 
and change ZP. Sample dilution using 
equilibrium supernatant is the best justified way 
to perform this dilution. Equilibrium supernatant 
is readily obtained by centrifugation [17-18].  
 
ZP AND TARGETED DRUG DELIVERY 
 
Nanoparticle surface is a very important 
consideration in targeting drug delivery. Indeed, 
once in the blood stream, conventional 
nanoparticles (no surface medication) and 
negatively charged particles can be rapidly 
opsonized and massively cleared by fixed 
macrophages. It is well known that the 
reticuloendothelial system (RES), mainly the liver 
and spleen, is a major obstacle to active 
targeting because of its ability to recognize these 
systems, remove them from systemic circulation, 
and consequently, avoid the effective delivery of 
the nano drug to organs other than those of the 
RES. Surface modification of these polymer 
nanoparticulate systems with hydrophilic 
polymers is the most common way to control the 
opsonization process and to improve the surface 
properties, especially surface charge, of the 
system [19]. 
 
Effect of ZP on cellular uptake 
 
Physicochemical properties, such as particle 
size, shape and surface charge, play a key role 
in the cellular uptake of nanoparticles. The 
uptake of nanoparticles by cells can be viewed 
as a two step process: first, a binding step on the 
cell membrane and second, the internalization 
step [20]. The attachment of nanoparticles to cell 
membrane seems to be most affected by the 
surface charge of the particles [21-22]. Variation 
of the particle surface charge could potentially 
control binding to the tissue and direct NPs to 
cellular compartments both in vitro and in vivo. 
Cellular surfaces are dominated by negatively 
charged sulphated proteoglycans moleculs that 
play pivotal roles in cellular proliferation, 
migration, and motility [23-24]. Cell surface 
proteoglyans consist of a core protein anchored 
to the membrane and linked to one or more 
glycosaminoglycan side chains (heparan, 
dermatan, keratan or chondrotine sulfates) to 
produce a structure that extends away from the 
cell surface.  
 
Glycosaminoglycans are highly anionic, and 
interaction between proteoglycans and NP 
shells, if positively charged, tend to be largely 
ionic [25]. Once inside the cell, degradation of 
polymers may occur, but targeting specific 
intracellular organelles is possible depending on 
the surface charge and attached ligands [26]. 
Nanoparticles with higher surface charge bound 
strongly to the cell membrane and showed a 
higher cellular uptake, where electrostatic 
interactions between the anionic membrane and 
cationic nanoparticles facilitate the uptake. After 
the adsorption of the nanoparticles on the cellular 
membrane, the uptake occurs via several 
possible mechanisms such as pinocytosis, non-
specific or receptor-mediated endocytosis or 
phagocytosis [27-28].  
 
The uptake of cerium oxide nanoparticles as a 
function of the surface charge of the particles 
was studied by Patil et al. Their results showed 
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that nanoparticles with ZP of - 43 mV have the 
highest cellular uptake compared with other 
formulations with less negative charge and/or 
positive surface charge. Nanoparticles show a 
high affinity for cellular membrane mainly due to 
electrostatic interactions [23]. It is already known 
that cell membranes have large negatively 
charged domains, which should repel negatively 
charged nanoparticles. The previous study on 
A549 cells showed that these cells indicated 
mean ZP of -10.2 mV with deviation of ±19.7 mV. 
The authors concluded that in that case, there 
are few cationic sites for adsorption of negatively 
charged particles. Previous literature suggested 
that the negatively charged particles bind at the 
cationic sites in the form of clusters [21] because 
of their repulsive interactions with the large 
negatively charge domains of cell surface. 
Moreover, the nanoparticles, already bound on 
the cell surface present a reduced charge density 
that may favor adsorption of other free particles. 
Totally, it seems, the high cellular uptake of 
negatively charged nanoparticles in their study, is 
related first to the non-specific process of 
nanoparticles adsorption on the cell membrane 
and second to formation of nanoparticle clusters. 
Studies by Limbach et al. on human lung 
fibroblast cells also indicated that cells rapidly 
adsorb negatively charged ceria nanoparticles 
[29]. The adsorption of the negatively charged 
particles at the positively charged sites via 
electrostatic interaction can lead to localized 
neutralization and a subsequent bending of the 
membrane favoring in turn endocytosis for 
cellular uptake [30]. Thus the formulation of 
nanoparticles with different surface properties 
can influence their cellular uptake and 
intracellular distribution [31-32] and it is possible 
to localize the nanoparticles to specific 
intracellular targets (lysosomes, mitochondria, 
cytoplasm and etc) by modifying their surface 
charge [21].  
 
There are some investigations that show the 
effect of surface charge in this regard. For 
example polymer charge density of dendrimers 
was found to significantly impact membrane 
permeability. The most densely charged polymer 
facilitates the transport of dye molecule across 
the membrane [33]. Other investigation showed 
that lipid coating of ionically charged nano 
particles was able to increase endothelial cell 
layer crossing 3 or 4 fold compared with 
uncoated particles, whereas nanoparticles 
coating of neutral particles did not significantly 
alter their permeation characteristics across the 
endothelial cell monolayer [34]. 
In an interesting investigation, histidine was 
partially substituted in the amino group of glycol 
chitosan self-assembled nanoparticles. Since 
histidine is strongly cationic at acidic pH, it 
interacts with negatively charged endosomal 
membranes, induces influx. The efficiency of 
drug delivery was significantly enhanced 
probably due to this interaction and the 
destabilization of endosomal membrane (Fig 1) 
[35]. Following cellular uptake, nanoparticles are 
transported to primary endosomes and to sorting 
endosomes. A fraction of nanoparticles can be 
recycled back to the exterior of cell by mean of 
exocytosis, while the rest reaches secondary 
endosomes. Secondary endosomes fuse with 
lysosomes to form endo-lysosome and the 
efficiency of cytoplasmic delivery is governed by 
the ease and rapidity of escape of nanoparticles 
from endo-lysosome. Previous literatures 
proposed and confirmed that the surface charge 
reversal of nanoparticles in the acidic pH of 
endo-lysosomes was responsible for the endo-
lysosomal escape of nanoparticles. Therefore, 
surface modification of nanoparticles can be 
attempted in order to influence targeting of drugs 
either to endo-lysosomes or to cytoplasm [36]. 
 
Effect of ZP on skin drug delivery systems 
 
Transdermal drug administration systems have 
been limited to drugs with the right combination 
of molecular weight, lipophilicity and charge [36]. 
Cationic compounds can also have a positive 
effect on skin permeation, since the skin carriers 
a negative surface charge due to phosphatidyl 
choline [37] and carbohydrates [38] found in 
mammalian cells and contain negatively charged 
groups [39]. Percutaneous penetration implies 
several steps. The release of a drug through skin 
will depend on the physicochemical properties of 
the drug itself combined with the influence of the 
vehicle to alter the drug penetration profile [40]. 
The positively charged nanoemulsions containing 
phytosphingosine (PS) were found to be more 
effective in terms of skin diffusion of 
fludrocortisones acetate and flumethasone 
pivalate through porcine skin than the negatively 
charged ones [41]. As mentioned, the interaction 
of nanoemulsions with skin depends upon a 
number of factors including also the electrical 
charge of the droplets. The results obtained 
suggested that positively charged particles of the 
nanoemulsion systems are able to carry 
efficiently fludrocortisone acetate and 
flumethasone pivalate into the skin and 
subsequently promote the penetration of the 
drugs through skin. The degree of skin binding is 
probably more important with the positively 
charged particles than with the negatively one as 
it is known that the skin is negatively charged at 
neutral pH. 
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Figure 2: The zeta potential of an aqueous suspension of nanospheres with pH values adjusted between 2 and 
12. Dashed arrows indicate the pH range between which the zeta potential of the nanoparticle formulation falls 
between +30 and −30 mV [42]. 
 
A novel transdermal delivery device, 
microneedle, mediated for delivery of 
nanoparticles into human skin, was studied on 
the permeation of nanoparticles through 
microchannels created within the skin surface. 
The zeta potential of nanoparticle formulations 
was measured at discriminate pH values 
between 2 and 12. Fig. 2 illustrated the direct 
influence of pH on the zeta potential of a colloidal 
particle and from this data an isoelectric point 
(the pH value of a colloidal formulation at which 
the zeta potential becomes 0 mV) of 
approximately pH 5 was calculated. In simple 
terms, an isoelectric value of pH 5 means that 
within this particular aqueous environment 
hydrogen ions are required to neutralise what 
must be a dominant negative charge on the 
surface of the nanoparticle. Therefore, although 
the nanoparticles have been functionalized to 
include reactive amine groups, it is negatively 
charged sulphate groups (created on the surface 
of the nanoparticle during the polymerization 
process) which contribute more significantly to 
the surface potential of the particle. The ability to 
reverse the zeta potential of nanoparticles, by 
adjustment of pH, was utilised to investigate the 
influence of a particles surface potential on its 
permeation through microconduits. It was shown 
that at pH of 7.4 (physiological pH) fluorescent 
nanospheres possessed a negative zeta 
potential (−40mV) whilst at pH 3 the surface 
potential of fluorescent nanospheres was 
reversed, i.e. the zeta potential was 
approximately +40mV. However the pH of the 
receptor phase in all Franz-type diffusion cells 
was measured both before and after each 
experiment and indicated that the desired pH 
was maintained for the duration of the 
experiment. At pH 7.4, where both the 
nanospheres and the membrane surface 
possess negative zeta potentials, diffusion 
through 10 μm pores occurred rapidly. After 4 h 
almost 80% of the applied formulation was 
detected in the receptor phase. At this stage, the 
concentration of nanoparticles is approaching 
equivalence across the membrane, suggesting 
that permeation in this model is a simple diffusive 
process and that equilibrium can be reached in a 
relatively short period of time (Fig 2) [42].  
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Effect of ZP on tumor cells targeting 
 
Cell surfaces, especially cancer cell surfaces, are 
usually charged negatively due to the 
translocation of negatively charged constituents 
of the inner layer of the cell membrane (e.g., 
phosphatidylserine, anionic phospholipids, 
glycoproteinsand proteoglycans) to the cell 
surfaces in the case of cancers [43]. The 
increased uptake of chitosan-modified paclitaxel-
loaded PLGA nanoparticles (C-NPs) into the cell 
at lower pH medium appears to be attributable in 
part to the electrostatic interaction between the 
positive charge of C-NPs and negative charge of 
the cancer cell surfaces [44]. Evidence 
accumulated during the past 50 years shows that 
the pH of most solid tumors in patients ranges 
from 5.7 to 7.8 with a mean value of 7.0. 
Moreover, greater than 80% of these measured 
values are smaller than pH 7.2 [45]. Tumor 
tissues contain large, acid-outside plasma pH 
gradients, while normal tissues generally have 
alkaline-outside pH gradients [46]. Therefore, the 
extracellular pH of malignant tumors is 
significantly lower than that of normal tissues 
under physiological conditions [47]. As the pH 
became acidic, the zeta potential of NPs became 
positive, which enhanced the electrostatic 
interaction between the C-NPs and tumor 
tissues. In addition, negative charges on the 
endothelial cell membranes of the tumor 
vasculature might have potentiated the 
electrostatic interaction between positively 
charged nanoparticles and tumors. Thus, these 
two factors – more positive charges of C-NPs at 
the tumor site and more negative charges of 
tumor cells/vasculature – appear to be 
responsible for the tumor-specific accumulation 
of C-NPs. This method used to accelerate in vitro 
uptake of coumarin 6 to cancer cells, enhanced 
cytotoxicity of paclitaxel and increased in vivo 
accumulation of coumarin 6 in tumor-bearing 
lungs [48].  
 
Cationic liposomal doxorubicin (LPs-DOX) and 
paclitaxel (LPs-PTX) were used for targeting the 
Fibroblast growth factor receptors (FGFRs) 
which are overexpressed on the surface of a 
variety of tumor cells. Biodistribution study in B16 
tumor-bearing mice showed that truncated 
human basic fibroblast growth factor peptide 
which was attached to the surface of cationic 
liposomal paclitaxel (tbFGF-LPs-PTX) achieved 
7.1-fold accumulation of paclitaxel in tumor tissue 
than those of free paclitaxel [49]. The anionic 
diblock copolymer of polymethacryloyl 
sulfadimethoxine (PSD) was complexed with 
cationic TAT of the micelles to achieve the final 
carrier, which could systemically shield the 
micelles and expose them at slightly acidic tumor 
pH. Zeta potential measurements showed a 
trend substantiating the shielding/deshielding 
process. Flow cytometry and confocal 
microscopy showed significantly higher uptake of 
TAT micelles at pH 6.6 compared to pH 7.4, 
indicating shielding at normal pH and deshielding 
at tumor pH. Confocal microscopy indicated that 
the TAT not only translocates into the cells but is 
also seen on the surface of the nucleus. From pH 
8.0 to 6.8 the zeta potential was around zero 
indicating complete shielding of TAT and from 
6.6 to 6.0 the zeta potential was increased to 6.0 
mV, which is the same as the zeta potential 
measured for TAT micelle alone, implicating the 
de-shielded TAT. The TAT peptide has high 
positive charge still the zeta potential of the 
micelles is low, this is attributed to the low 
surface density of TAT conjugated to the micelle 
surface [50]. 
 
Drug delivery systems may bring us a step closer 
to a safe and universal targeting system for 
acidic solid tumors. The vascular permeability is 
limited by the size and charge of the drug as well 
as the structures of the vessel wall particularly 
the basement membrane [51]. Direct access to 
intravenously administered agent, rapid 
proliferated of endothelial cells and over 
expression of negatively charged functional 
groups along vessels are potentially exploitable 
feature of tumors [51-52]. 
 
Nanoparticleas with positive charge are 
preferentially taken up by the tumors [53-54]. and 
retained for a longer time span compared to 
negatively charge or neutral particles [53] 
because phosphatidyl serine, a negatively 
charge residue, is translocated to the surface of 
the cancer cells [59] and nanoparticles with 
positive charge can translocated by the tumor 
cells through either fluid phase endocytosis, or 
charge interactions and ligand receptor docking 
[55]. Cationic drug carriers can also be used to 
enhance the interaction of anti-angiogenic agents 
with integrins. Integrins are involved in cell 
invasion and metastasis and in signaling 
processes [38]. This strategy to target the tumor 
cells is named passive targeting or the enhanced 
permeability and retention (EPR) effect wherein 
carriers of appropriate particle size, charge and 
stability will preferentially accumulate in tumors 
[56]. Investigations show that cationic liposomes 
bind by electrostatic interactions to negatively 
charge surface in tumor endothelial cells [57]. 
Increasing the charge of cationic PEGylated 
liposomes decrease their accumulation in the 
spleen and blood while increasing their uptake by 
the liver and an increasing in the accumulation of 
liposomes in tumor vessels [58]. Moreover, the 
presence of charged functionalities on the 
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nanoparticles surface may increase nonspeciffic 
uptake and making the preparation less effective 
in targeting, Because negative charge is 
available on other tissues too [34]. For example 
positive nanoparticles can interact with negative 
plasma proteins and form nanoparticles-proteins 
aggregates [54]. 
 
Effect of ZPs on brain targeting 
 
Transportation of nanoparticles from the BBB is 
involving electrostatic interaction between a 
positively charged ligand and the negatively 
charged membrane of cells at the BBB that is 
named adsorptive mediated endocytosis (AME) 
[60]. Positive zeta potensial on nanoparticles can 
help the transportation of nanoparticles from 
BBB. The anionic sites were located on the 
luminal surface of brain capillaries is due to the 
sialic acid residues of glycoproteins. AME of 
nanoparticles can accurs in other ways like 
choline transporter in the brain. These carriers 
are consisting of anionic sites which interact with 
positively charged quaternary ammonium group 
[57]. 
 
There are some established works in the delivery 
of positive proteins or positive nanoparticles to 
the brain. For example cationazed albumin 
nanoparticles [35] or immunogolubins [57] were 
efficiently transport across the BBB. The other 
example is the etoposide-loaded positively 
charged tripalmitin nanoparticles that achieve 
highest brain concentration when compared to 
negatively charged etoposide incorporated 
tripalmitin nanoparticles and etoposide solution 
[61]. 
 
Methoxy PEG–PLA and maleimide PEG–PLA 
were synthesized via ring opening polymerization 
of L-lactide and used to prepare PEGylated 
nanoparticles (NPs) loaded with sulpiride by 
emulsification and solvent evaporation method. 
Thiolated cationized bovine serum albumin 
(CBSA) was conjugated through the maleimide 
function to the NPs. Characterized particles 
(mean particle size 329 ± 44 nm) indicated the 
conjugation of cationic albumin to NPs (zeta 
potential shift from -39 mV to -19 mV). 
Fluorescence showed a high accumulation of 
CBSA-NPs in brain compared to that of BSA-
NPs and uncoated NPs supported by plasma 
and urine profile. ZP represents the difference in 
the electrical charge between the dense layers of 
ions that surrounds the particle and the charge of 
the bulk of the suspended fluid surrounding the 
particles.  
 
The ZP of CBSA-NPs can be attributed to two 
factors; first, the PEG surface shielding effect on 
offsetting the negative charge of the PLA 
segments in the NPs core and second, the CBSA 
cationization degree. The ZP measured for 
uncoated NPs and CBSA-NPs were around -39 
mV and -19 mV, respectively. The potential 
difference in ZP values represents successful 
attachment of CBSA to NPs and change in 
surface charge property of the particle. Although 
ZP for the obtained particle was towards 
negative side, it supported the hypothesis that 
overall, at the local microenvironment 
surrounding each CBSA milieu on the NPs 
surface, the net electrical charge would be 
positive and facilitating CBSA at periphery of the 
NPs to electrostatically bind the negatively 
charged residues on the endothelial cells of BBB. 
Therefore, it could be assumed that due to 
relatively less negative surface charge of the 
particle, it gets attracted and adsorbed to the 
BBB endothelial cells and thus enhances the 
availability (Fig 3) [62]. 
 
The procationic liposomes (PCLs) were neutral 
or negatively charged at physiological pH, and 
when they touched brain capillary endothelial 
cells with the help of a brain-targeting ligand, 
lactoferrin (Lf), they were changed into cationic 
liposomes (CL). The PCLs and lactoferrin-
modified procationic liposomes (Lf-PCLs) with 
different CHETA/Lf ratio were prepared and 
characterized in previous literatures. The primary 
brain capillary endothelial cells (BCECs) were 
cultured to investigate the potential cytotoxicity 
and uptake of liposomes in vitro. An in vitro 
model of the blood–brain barrier (BBB), 




Figure 3’ The effect of zeta potential on brain 
targeting of nanoparticles [62]. 
 
(ACs), was employed to evaluate the ability and 
mechanisms of liposomes to cross endothelial 
cells. The liposome uptake by the mouse brain in 
vivo was detected by HPLC-fluorescence 
analysis. The results indicated that compared 
with the conventional liposomes and CLs, PCL 
and Lf-PCLs showed an improved performance 
in the uptake efficiency and cytotoxicity. Besides 
the uptake mediated by clathrin-dependent 
endocytosis of PCL, Lf-PCL crossed the BCECs 
through lipid raft/caveloae-mediated endocytosis. 
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The endocytosis involved in the transport of Lf-
PCL crossing BBB was mediated by both 
receptor- and absorption-mediated transcytosis 
compared with the conventional liposomes. The 
zeta potential of coumarin-6 loaded PCLs and Lf-
PCLs were from −32.3 to −4.3 mV. And it was 
shown that the positively charged Lfs might have 
attached onto the surface of the PCLs. The 
comparison of zeta-potential of PCLs and Lf-
PCLs further confirmed the interaction of Lfs with 
PCLs [63]. 
 
The BBB penetration and distribution of 
PEGylated PFMSNs and FMSNs in rat brain 
were investigated not only at the cellular level 
with Confocal laser scanning microscopy 
(CLSM), but also at the subcellular level with 
transmission electron microscopy (TEM). The 
results provide direct evidence that PEGylated 
PFMSNs could penetrate the BBB and spread 
into the brain parenchyma. According to the 
values of f-potential, the surface charges of 
FMSNs changed from negative (-22.43 mV) to 
positive (+18.93 mV) as a result of PAMAM 
conjugation, then the charge changed to nearly 
neutral (+1.49 mV), indicating a further 
modification of PEG [64]. 
 
In order to develop a novel brain-targeting 
delivery system for anti-neuroexcitation peptide 
(ANEP), a water-soluble cationic chitosan 
derivative, N-trimethyl chitosan chloride (TMC), 
was synthesized. The nanoparticles have a 
positive zeta potential of 30.7 mV. Absorption-
mediated transcytosis (AMT) is triggered by an 
electrostatic interaction between the positively 
charged moiety of the nanoparticles and a 
negatively charged plasma membrane surface 
region on the brain capillary endothelium. 
Fluorescent micrographs also showed the 
corresponding brain biodistribution results in the 
four groups [65]. Huang et al. [66] proved that the 
uptake of chitosan nanoparticles by A549 cells 
was initiated by electrostatic interactions 
between the nanoparticles and the cell 
membrane and Amidi et al. found that FITC–
albuminassociated TMC nanoparticles could be 
transported across the nasal mucosa due to 
intracellular uptake by epithelial and NALT cells 
in a series of in vivo uptake studies [67].  
 
Effect of ZP on multi drug resistance (MDR) 
 
Multi-drug resistance (MDR) of tumor cells is a 
major obstacle to the success of cancer 
chemotherapy. MDR is mainly due to the over 
expression of the plasma membrane P-
glycoproteins, which is capable of extruding 
various generally positively charged xenobiotics 
including some anticancer drugs. Indeed, to be 
effective to overcome MDR three criteria need to 
be fulfilled: 1) particulate structure should adhere 
to the cell membrane, providing a concentration 
gradient. 2) The drug release and nanoparticles 
degradation should occur simultaneously 3) an 
ion pair should form in order to mask the positive 
charge of the drug. So in this way by masking the 
ZP in the surface of the nanoparticles could be 
overcome MDR [52]. 
 
Tumor drug resistance significantly limits the 
success of chemotherapy in the clinic. Tumor 
cells utilize multiple mechanisms to prevent the 
accumulation of anticancer drugs at their 
intracellular site of action. In previous studies the 
anticancer efficacy of doxorubicin in combination 
with photodynamic therapy was investigated 
using methylene blue in a drug-resistant mouse 
tumor model. Surfactant-polymer hybrid 
nanoparticles formulated using an anionic 
surfactant, Aerosol-OT™ (AOT), and a naturally 
occurring polysaccharide polymer, sodium 
alginate, were used for synchronized delivery of 
the two drugs. Their proposed model for AOT 
alginate nanoparticles – drug-loaded, calcium-
crosslinked alginate core, surrounded by one or 
more bilayers composed of AOT, suggested that 
only the negative charges present in the core of 
the nanoparticle matrix (carboxyl groups in 
alginate) are involved in electrostatic interactions 
with weakly basic drug molecules. Thus, 
negative charges (sulfonate of AOT) on the 
surface of nanoparticles contribute to the 
negative zeta potential of drug-loaded AOT-
alginate nanoparticles [68]. 
The cellular uptake and cytotoxicity of targeted 
compare with nontargeted doxorubicin (DOX)-
loaded 9 poly (D,L-lactide co-glycolide) (PLGA) 
nanoparticle (NP) drug delivery systems in drug-
resistant ovarian (SKOV-3) and uterine (MES-
SA/10 Dx5) cancer cell lines. They concluded 
that cellular uptake and cytotoxicity of DOX can 
be improved in MES-SA/Dx5 cells by loading 
DOX into PLGA NPs. The zeta potentials of the 
DOX-loaded NPs with and without antibody (IgG) 
conjugation were –1.3 ± 3.8 mV and 290 –13.2 ± 
2.3 mV, respectively [69].  
 
Paclitaxel-loaded nanoparticles were prepared 
by a water–acetone solvent displacement 
method using commercial PCL and self-
synthesized PCL/Poloxamer 188 compound, 
respectively. It is also an important factor in 
determining their interaction with the cell 
membrane in vivo, which is usually negatively 
charged. In addition, from the zeta potential data, 
we can roughly know the dominated component 
on the particles surface. As shown in Table 1, the 
zeta potential of PCL/Poloxamer 188 
nanoparticles is -22.77 mV Compared with PCL 
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nanoparticles, whose zeta potential is around -
35.45 mV, a great increase in the absolute value 
of the PCL/Poloxamer 188 nanoparticle surface 
charge could be observed. Since Poloxamer 188 
is non-ionic, this surface charge increase 
demonstrated the presence of a Poloxamer 188 
layer on the surface, which shifted the shear 





Zeta potential is one of important propertied 
which could play a major role in effectiveness of 
nanomedicine. Either targeted therapy or stability 
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